These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 2784716)

  • 1. Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin.
    van der Meijden AP; Steerenberg PA; van Hoogstraaten IM; Kerckhaert JA; Schreinemachers LM; Harthoorn-Lasthuizen EJ; Hagenaars AM; de Jong WH; Debruijne FM; Ruitenberg EJ
    Cancer Immunol Immunother; 1989; 28(4):287-95. PubMed ID: 2784716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer.
    Zlotta AR; Drowart A; Huygen K; De Bruyn J; Shekarsarai H; Decock M; Pirson M; Jurion F; Palfliet K; Denis O; Mascart F; Simon J; Schulman CC; Van Vooren JP
    Clin Exp Immunol; 1997 Jul; 109(1):157-65. PubMed ID: 9218839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of purified protein derivative prior to intravesical bacillus Calmette-Guérin for the treatment of patients with non-muscle invasive bladder cancer.
    Zawky M; Elsayed A; Awadallah A; Abdelhalim A; Abolenein H; Shokeir A
    Minerva Urol Nephrol; 2024 Aug; 76(4):474-483. PubMed ID: 38757774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors.
    Lüftenegger W; Ackermann DK; Futterlieb A; Kraft R; Minder CE; Nadelhaft P; Studer UE
    J Urol; 1996 Feb; 155(2):483-7. PubMed ID: 8558641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superficial bladder tumors and increased reactivity against mycobacterial antigens before bacillus Calmette-Guerin therapy.
    Zlotta AR; Drowart A; Van Vooren JP; Shekarsarai H; De Cock M; Pirson M; Palfliet K; Jurion F; Simon J; Schulman CC; Huygen K
    J Urol; 1998 Jun; 159(6):1885-91. PubMed ID: 9598481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.
    Zlotta A; Drowart A; van Vooren JP; Simon J; Schulman CC; Huygen K
    Acta Urol Belg; 1994 Sep; 62(3):63-8. PubMed ID: 7976857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
    Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
    J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients.
    Winters WD; Lamm DL
    Cancer Res; 1981 Jul; 41(7):2672-6. PubMed ID: 7018669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological aspects of intravesical administration of Bacillus Calmette-Guérin (BCG) in the guinea pig.
    van der Meijden AP; de Jong WH; de Boer EC; Steerenberg PA; Debruyne FM; Ruitenberg EJ
    Urol Res; 1989; 17(1):47-55. PubMed ID: 2922891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review.
    Patard JJ; Saint F; Velotti F; Abbou CC; Chopin DK
    Urol Res; 1998; 26(3):155-9. PubMed ID: 9694595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical and intradermal Bacillus Calmette-Guérin application. A phase I study to the toxicity of a Dutch Bacillus Calmette-Guérin preparation in patients with superficial bladder cancer.
    Schreinemachers LM; van der Meijden AP; Wagenaar J; Steerenberg PA; Feitz WF; Groothuis DG; Tiesjema RH; de Jong WH; Debruyne FM; Ruitenberg EJ
    Eur Urol; 1988; 14(1):15-21. PubMed ID: 2963745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?
    Zlotta AR; van Vooren JP; Huygen K; Drowart A; Decock M; Pirson M; Jurion F; Palfliet K; Denis O; Simon J; Schulman CC
    Eur Urol; 2000 Apr; 37(4):470-7. PubMed ID: 10765079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sequential intravesical administration of mitomycin C and bacillus Calmette-Guérin on the immune response in the guinea pig bladder.
    Balemans LT; Vegt PD; Steerenberg PA; De Boer EC; Van Swaaij A; De Vries RE; Van der Meijden AP; Den Otter W
    Urol Res; 1994; 22(4):239-45. PubMed ID: 7871637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.
    De Boer EC; De Jong WH; Van Der Meijden AP; Steerenberg PA; Witjes JA; Vegt PD; Debruyne FM; Ruitenberg EJ
    Cancer Immunol Immunother; 1991; 33(6):411-6. PubMed ID: 1878894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study.
    Witjes JA; Fransen MP; van der Meijden AP; Doesburg WH; Debruyne FM
    Urol Int; 1993; 51(2):67-72. PubMed ID: 8351757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunoresponse study of intravesical instillation of Taipei-NIPM bacillus Calmette-Guérin.
    Chang SY; Yu DS; Ma CP; Liau MY
    Eur Urol; 1992; 21(1):52-7. PubMed ID: 1606984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti-tumoral microenvironment: Novel role of trained immunity.
    Atallah A; Grossman A; Nauman RW; Paré JF; Khan A; Siemens DR; Cotechini T; Graham CH
    Int J Cancer; 2024 Jul; 155(2):352-364. PubMed ID: 38483404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.